Other soluble hypoxia-related biomarkers were assessed in patient serum with NSCLC including VEGF and basic fibroblast growth factor (bFGF): similar results were reported with poorer survival rates among patients with high serum concentrations of circulating VEGF and bFGF [147]. This evidence concerns the gene FGF2 and non-small cell lung carcinoma.